Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical Co Ltd develops, manufactures, and sells pharmaceutical and personal care products in Japan and internationally, generating revenue primarily through the sale of over-the-counter medications and cosmetics.
Business. Rohto Pharmaceutical Co Ltd (4527.T) is a Japanese pharmaceutical company headquartered in Japan and primarily listed on the Tokyo Stock Exchange. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. As detailed segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the broader pharmaceuticals market.
Analyst recommendations
11 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Rohto Pharmaceutical Co Ltd (4527.T) is a Japanese pharmaceutical company headquartered in Japan and primarily listed on the Tokyo Stock Exchange. The firm operates within the healthcare sector, specifically focusing on the development and sale of pharmaceutical products. As detailed segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the broader pharmaceuticals market.
Rohto maintains a strong liquidity position with a current ratio of 2.3 and cash and equivalents of ¥77.16 billion, which supports operational flexibility and debt servicing. The company's liquidity FPT score of 0.85 indicates a low risk of short-term financial distress, supported by free cash flow of ¥26.46 billion and operating cash flow of ¥37.13 billion.
Profitability metrics show a return on equity of 11.92% and return on assets of 7.35%, both exceeding the industry median for Pharmaceuticals. Operating income of ¥36.87 billion and net income of ¥31.01 billion reflect strong margins, though gross profit of ¥174.94 billion suggests moderate cost control.
Geographically, Rohto's revenue is concentrated in Japan, with limited exposure to international markets. Segment-wise, the company operates as a single business unit, with no material diversification across product lines or geographic regions.
The company's growth trajectory is stable, with revenue of ¥308.63 billion in the latest period. Analysts project a mean price target of ¥2,888, with a median of ¥2,925, indicating moderate upside potential. The mean recommendation of 2.18 suggests a consensus of "buy" or "hold".
Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.25 and long-term debt of ¥64.67 billion are manageable, and the company has not issued new shares recently. No dilution pressure is expected in the near term.
Recent events include no material filings or transcripts that would suggest a shift in strategy or financial distress. The company's capital expenditures of ¥10.56 billion were funded internally, and no external financing was required.
- Rohto maintains a strong liquidity position with a current ratio of 2.3 and ¥77.16 billion in cash and equivalents.
- The company's profitability metrics (ROE of 11.92%, ROA of 7.35%) outperform industry medians.
- Revenue is concentrated in Japan, with limited international diversification.
- Analysts project a mean price target of ¥2,888, with a "buy" or "hold" consensus.
- No immediate liquidity or dilution risks are present, with a debt-to-equity ratio of 0.25.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 148,84 |
| Revenue | —no estimate | —no estimate | 338,9B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Rohto Pharmaceutical Co Ltd Market data — financials · 2026-05-26
- Rohto Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26
- Rohto Pharmaceutical Co Ltd Market data — ESG · 2026-05-26